ACS Medicinal Chemistry Letters
Page 6 of 7
(8) Rossi, F.; Diaz, L.; Wollam, A.; Panesso, D.; Zhou, Y.;
(22) Ni, S.; Wei, H.; Li, B.; Chen, F.; Liu, Y.; Chen, W.; Xu, Y.;
Qiu, X.; Li, X.; Lu, Y.; Liu, W.; Hu, L.; Lin, D.; Wang, M.; Zheng,
X.; Mao, F.; Zhu, J.; Lan, L.; Li, J. Novel Inhibitors of
Staphyloxanthin Virulence Factor in Comparison with Linezolid
1
2
3
4
5
6
7
8
Rincon, S.; Narechania, A.; Xing, G.; Di-G.; Di-Gioia, T. S.;
Doi, A.; Tran, T.T.; Reyes, J.; Munita, J. M.; Carvajal , L. P.;
Hernandez-Roldan, A.; Brandão, D.; van der Heijden, I. M.;
Murray, B. E.; Planet, P. J.; Weinstock, G. M.; Arias, C. A.
Transferable vancomycin resistance in a community-associated
MRSA lineage. N. Engl. J. Med. 2014, 370 (16), 1524-1531.
(9) Global priority list of antibiotic-resistant bacteria to guide
research, discovery, and development of new antibiotics; World
and
Vancomycin
versus
and
Methicillin-Resistant,
Vancomycin-Intermediate
Linezolid-Resistant,
Staphylococcus aureus Infections in Vivo. J. Med. Chem. 2017,
60 (19), 8145-8159.
(23)Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.;
Kobayashi, I.; Cui, L.; Oguchi, A.; Aoki, K. I.; Nagai, Y.; Lian, J.;
Ito, T.; Kanamori, M.; Matsumaru, H.; Maruyama, A.; Murakami,
H.; Hosoyama, A.; Mizutani-Ui, Y.; Takahashi, N. K.; Sawano, T.;
Inoue, R. i.; Kaito, C.; Sekimizu, K.; Hirakawa, H.; Kuhara, S.;
Goto, S.; Yabuzaki, J.; Kanehisa, M.; Yamashita, A.; Oshima, K.;
Furuya, K.; Yoshino, C.; Shiba, T.; Hattori, M.; Ogasawara, N.;
Hayashi, H.; Hiramatsu, K. Whole genome sequencing of
meticillin-resistant Staphylococcus aureus. Lancet 2001, 357,
1225-1240.
(24) Wilson, P.; Andrews, J. A.; Charlesworth, R.; Walesby, R.;
Singer, M.; Farrel, D. J.; Robbins, M. Linezolid resistance in
clinical isolates of Staphylococcus aureus. J. Antimicrob.
Chemother. 2003, 51 (1), 186–188.
(25) David, M. Z.; Daum, R. S. Community-associated
methicillin-resistant Staphylococcus aureus: epidemiology and
clinical consequences of an emerging epidemic. Clin. Microbiol.
Rev. 2010, 23 (3), 616-687.
Health
Organization,
9
-antibiotic-resistant-bacteria/en/ (accessed February 27, 2016).
(10) Dickey, S. W.; Otto, M.; Different drugs for bad bugs:
antivirulence strategies in the age of antibiotic resistance. Nat.
Rev. Drug Discovery 2017, 16 (7), 457-471.
(11) Casadevall, A.; Pirofski, L. A. Host-Pathogen Interactions:
Redefining the Basic Concepts of Virulenlence and Pathogenicity.
Infect. Immun. 1999, 67 (8), 3703-3713.
(12) Clauditz, A.; Resch, A.; Wieland, K. P.; Peschel, A.; Götz,
F.; Staphyloxanthin Plays a Role in the Fitness of Staphylococcus
aureus and Its Ability to Cope with Oxidative Stress. Infect.
Immun. 2006, 74 (8), 4950-4953.
(13) Khodade, V. S.; Chandra, M. S.; Banerjee, A.; Lahiri, S.;
Pulipeta, M.; Rangarajan, R.; Chakrapani, H. Bioreductively
Activated Reactive Oxygen Species (ROS) Generators as MRSA
Inhibitors. ACS Med. Chem. Lett. 2014, 5 (7), 777-781.
(14) Oldfield, E.; Feng, X. Resistance-resistant antibiotics.
Trends Pharmacol. Sci. 2014, 35 (12), 664-674.
(15) Wieland, B.; Feil, C.; Gloria-Maercker, E.; Thumm, G.;
Lechner, M.; Bravo, J. M.; Poralla, K.; Götz, F. Genetic and
biochemical analyses of the biosynthesis of the yellow carotenoid
4, 4’-diaponeurosporene of Staphylococcus aureus. J. Bacteriol.
1994, 176 (24), 7719-7726.
(16) Liu, C. I.; Liu, G. Y.; Song, Y.; Yin, F.; Hensler, M. E.;
Jeng, W. Y.; Nizet, V.; Wang, A. H.; Oldfield, E. A cholesterol
biosynthesis inhibitor blocks Staphylococcus aureus virulence.
Science 2008, 319, 1391-1394.
(17) Song, Y.; Lin, F. Y.; Yin, F.; Hensler, M.; Rodrígues
Poveda, C. A.; Mukkamala, D.; Cao, R.; Wang, H.; Morita, C. T.;
Gonzalez Pacanowska, D.; Nizet, V.; Oldfield, E.
Phosphonosulfonates are potent, selective inhibitors of
dehydrosqualene synthase and staphyloxanthin biosynthesis in
Staphylococcus aureus. J. Med. Chem. 2009, 52 (4), 976-988.
(18) Song, Y.; Liu, C. I.; Lin, F. Y.; No, J. H.; Hensler, M.; Liu,
Y. L.; Jeng, W. Y.; Low, J.; Liu, G. Y.; Nizet, V.; Wang, A. H. J.;
Oldfield, E. Inhibition of staphyloxanthin virulence factor
biosynthesis in Staphylococcus aureus: in vitro, in vivo, and
crystallographic results. J. Med. Chem. 2009, 52 (13),
3869-3880.
(19) Chen, F.; Di, H.; Wang, Y.; Cao, Q.; Xu, B.; Zhang, X.;
Yang, N.; Liu, G.; Yang, C. G.; Xu, Y.; Jiang, H.; Lian, F.; Zhang,
N.; Li, J.; Lan, L. Small molecule targeting of a diapophytoene
desaturase inhibits S. aureus virulence. Nat. Chem. Biol. 2016,
12 (3), 174-179.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(26) de Matos P. D.; de Oliveira T. L.; Cavalcante F. S.;
Ferreira D. C.; Iorio N. L.; Pereira E. M.; Chamon R. C.; Dos
Santos K. R. Molecular markers of antimicrobial resistance in
methicillin-resistant Staphylococcus aureus SCCmec IV
presenting different genetic backgrounds. Microb. Drug. Resist.
April 5, 2016; DOI:10.1089/mdr.2015.0255
(20) Wang, Y.; Chen, F.; Di, H.; Xu, Y.; Xiao, Q.; Wang, X.;
Wei, H.; Lu, Y.; Zhang, L.; Zhu, J.; Sheng, C.; Lan, L.; Li. J.
Discovery of Potent Benzofuran-Derived Diapophytoene
Desaturase (CrtN) Inhibitors with Enhanced Oral Bioavailability
for the Treatment of Methicillin-Resistant Staphylococcus aureus
(MRSA) Infections. J. Med. Chem. 2016, 59 (7), 3215-3230.
(21) Wang, Y.; Di, H.; Chen, F.; Xu, Y.; Xiao, Q.; Wang, X.;
Wei, H.; Lu, Y.; Zhang, L.; Zhu, J.; Lan, L.; Li. J. Discovery of
Benzocycloalkane Derivatives Efficiently Blocking Bacterial
Virulence for the Treatment of Methicillin-Resistant S. aureus
(MRSA) Infections by Targeting Diapophytoene Desaturase
(CrtN). J. Med. Chem. 2016, 59 (10), 4831-4747.
ACS Paragon Plus Environment